Ion channels are critical to the function of both excitable and nonexcitable tissue. Yet, it is in the excitable tissues of skeletal muscle and the nervous system that one sees the most clearly defined manifestations of these disorders. Because of their accessibility to microelectrode studies, disorders of muscle membrane excitability feature prominently in the early description of channel disorders. Channelopathies typically refer to monogenic or acquired autoimmune disorders directly influencing individual channel function. However, with the evolving concept of what constitutes a channelopathy, a more expansive definition would include channel disorders resulting from pathologic states, either inherited or acquired, where channels are not the primary targets. Several pathologic states can result from a change in the number of nonmutated channels, thus altering membrane excitability. Such conditions, also termed transcriptional channelopathies, include hyperalgesia in nerve injury, ataxia in multiple sclerosis, and symptomatic epilepsy. Another recently described mechanism could be termed a post-transcriptional channelopathy. In myotonic dystrophy, myotonia is caused by a reduced number of muscle membrane chloride channels secondary to abnormal splicing of mRNA from a nonmutated chloride gene. The present issue of Neurotherapeutics will focus primarily on the more narrowly defined and well characterized neurologic channelopathies arising from mutations in ion channel genes.
The emerging knowledge about the genetically defined channel disorders has simultaneously clarified and complicated our understanding of these disorders. There is a surprising amount of phenotypic as well as genotypic heterogeneity for some disorders that were thought to be clinically and pathologically distinct. For example, mutations in SCN4A, the skeletal muscle sodium channel, can result in either muscle membrane inexcitability (periodic paralysis) 1 or muscle membrane hyperexcitability (myotonia). 2 Moreover, different mutations in the SCN4A can cause either hyperkalemic or hypokalemic periodic paralysis. 3 Additionally, whereas the causal genes for some conditions were predicted based on existing physiologic studies (e.g., chloride channel in myotonia congenita), others such the L-type calcium channel (CACNA1S) in hypokalemic periodic paralysis were a surprise. How mutations in a calcium channel essential in excitation-contraction coupling can result in transient muscle membrane depolarization and inexcitability has challenged our understanding of normal muscle electrophysiology.
There are a number of issues that arise in establishing effective therapies in the channelopathies. The phenotypic and genotypic heterogeneity, and incomplete understanding of the pathophysiology 4 described above, represent part of the challenge. Additionally, the structural similarities among many of the channels make it difficult to find agents that modify channel function in a tissue selective manner. 5 Perhaps the biggest challenge, however, is the rarity of these disorders and consequent difficulty in designing and conducting definitive therapeutic trials. 6 Some of these limitations can be overcome by the establishment of national and international research networks and the use of innovative study designs. The benefits of such studies could have potentially wider applications to more common causes of epilepsy 7 and headache.
